Leela Barham's profile photo

Leela Barham

England

Writer and Researcher at Freelance

Freelancing researcher and writer on the economics of healthcare.

Featured in: Favicon nih.gov Favicon informa.com (+2) Favicon pharmaphorum.com Favicon pmlive.com Favicon pharmexec.com Favicon chemistanddruggist.co.uk Favicon invesbrain.com Favicon p3pharmacy.co.uk Favicon biomedcentral.com Favicon citeline.com

Articles

  • Is money the only metric that really matters in UK’s VPAG? It shouldn’t be

    2 weeks ago | pharmaphorum.com | Leela Barham

    The UK’s Voluntary Scheme that covers pricing, access, and growth of branded medicines has been generating a lot of attention lately, mostly related to the billions being paid back by scheme members. Leela Barham makes the case that it’s a mistake to focus just on the money; instead, a wider view on the success of the scheme is needed, an approach seen in the metrics for the scheme.

  • Non-Submissions To England’s NICE Surge Across All Disease Areas

    1 month ago | insights.citeline.com | Leela Barham

    Non-Submissions To England’s NICE Surge Across All Disease Areas01 May 2025 • By Leela BarhamBlood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet. Pink Sheet analysis examined the impact of the failure of companies to submit evidence to England's HTA body NICE. (Shutterstock)

  • Buyer’s remorse: The UK’s VPAG

    2 months ago | pharmaphorum.com | Leela Barham

    Leela Barham takes stock of the debate surrounding the UK’s current pricing and access deal that caps NHS spend on branded medicines, after a higher-than-expected payback rate for 2025. With the ABPI wanting to change the scheme just over a year into its five-year term, it seems that they have buyer’s remorse.

  • NHS medicines spending in England in greater focus

    Mar 18, 2025 | pharmaphorum.com | Leela Barham

    Leela Barham provides a perspective on the ABPI blog that covers understanding NHS medicines spending in England. NHS stats on medicines spend exclude voluntary scheme rebatesOn 10th March, the ABPI’s Pinchas Kahtan posted a blog that discussed what statistics from the NHS Business Services Authority (NHBSSA) on medicines spend by the NHS tells the public.

  • NICE contribution to the cost per QALY threshold debate?

    Feb 6, 2025 | pharmaphorum.com | Leela Barham

    Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency and highlights the opportunity for stakeholders to build their case for change, a case that needs to be made to politicians, not NICE, over the next three years. In December 2024, Dr Jacoline Bouvy, programme director for medicines evaluation at NICE, published a blog that posed the question, should NICE’s cost-effectiveness thresholds change?

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
904
Tweets
492
DMs Open
No
Leela Barham
Leela Barham @leelabarham
1 Apr 24

RT @consiliumsci: By ⁦@leelabarham⁩ on our recent publication at ⁦@BMJ_Open⁩. ⁦@LSEHealthPolicy⁩ ⁦@KoustaMarina⁩ ⁦@HTAiOrg⁩ ⁦@ABPI_UK⁩ ⁦@NI…

Leela Barham
Leela Barham @leelabarham
21 Nov 23

RT @pharmaphorum: #NICE ran a webinar on 2nd November, setting out – ahead of formal consultation opening 21st November – plans to increase…

Leela Barham
Leela Barham @leelabarham
20 Nov 23

RT @pharmaphorum: #NICE ran a webinar on 2nd November, setting out – ahead of formal consultation opening 21st November – plans to increase…